CN115315248A - 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途 - Google Patents
促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途 Download PDFInfo
- Publication number
- CN115315248A CN115315248A CN202180022370.3A CN202180022370A CN115315248A CN 115315248 A CN115315248 A CN 115315248A CN 202180022370 A CN202180022370 A CN 202180022370A CN 115315248 A CN115315248 A CN 115315248A
- Authority
- CN
- China
- Prior art keywords
- mitochondria
- plasma
- cells
- composition
- hair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003470 mitochondria Anatomy 0.000 title claims abstract description 99
- 239000000203 mixture Substances 0.000 title claims abstract description 89
- 230000001737 promoting effect Effects 0.000 title claims abstract description 13
- 230000003660 hair regeneration Effects 0.000 title abstract description 10
- 238000004519 manufacturing process Methods 0.000 title description 5
- 210000003780 hair follicle Anatomy 0.000 claims abstract description 36
- 230000004083 survival effect Effects 0.000 claims abstract description 23
- 230000032683 aging Effects 0.000 claims abstract description 22
- 230000004792 oxidative damage Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 102
- 230000002438 mitochondrial effect Effects 0.000 claims description 19
- 210000003491 skin Anatomy 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 230000003659 hair regrowth Effects 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 210000002768 hair cell Anatomy 0.000 claims 3
- 210000004209 hair Anatomy 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 10
- 230000004054 inflammatory process Effects 0.000 abstract description 10
- 210000000442 hair follicle cell Anatomy 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 62
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 60
- 238000002474 experimental method Methods 0.000 description 45
- 210000000642 hair follicle dermal papilla cell Anatomy 0.000 description 38
- 210000001519 tissue Anatomy 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 210000002540 macrophage Anatomy 0.000 description 16
- 230000006378 damage Effects 0.000 description 14
- 230000003779 hair growth Effects 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 210000000130 stem cell Anatomy 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 210000004761 scalp Anatomy 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 230000032677 cell aging Effects 0.000 description 7
- 150000003254 radicals Chemical class 0.000 description 7
- 239000005720 sucrose Substances 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 150000002978 peroxides Chemical class 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000011536 extraction buffer Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 3
- 230000008470 skin growth Effects 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 108010081589 Becaplermin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000000550 effect on aging Effects 0.000 description 2
- 230000002900 effect on cell Effects 0.000 description 2
- 238000012921 fluorescence analysis Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000009583 hair follicle growth Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 2
- 108010000685 platelet-derived growth factor AB Proteins 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000907745 Otacanthus azureus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- -1 ethylcarboxyl group Chemical group 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000008810 intracellular oxidative stress Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000007625 mitochondrial abnormality Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000004623 platelet-rich plasma Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/115—Platelets, megakaryocytes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
Abstract
本发明实施例提供一种促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途。包含线粒体的组合物可提高受损毛囊细胞的存活率、改善毛囊细胞的老化、改善毛囊细胞的氧化损伤及改善毛囊发炎现象，以达到促进毛发再生的目的。
Description
PCT国内申请，说明书已公开。
Claims (13)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992546P | 2020-03-20 | 2020-03-20 | |
| US62/992,546 | 2020-03-20 | ||
| PCT/CN2021/082117 WO2021185377A1 (zh) | 2020-03-20 | 2021-03-22 | 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115315248A true CN115315248A (zh) | 2022-11-08 |
Family
ID=77768010
Family Applications (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410329264.5A Pending CN118319951A (zh) | 2020-03-20 | 2021-03-19 | 修复肌腱损伤的组合物 |
| CN202311570784.7A Pending CN117357559A (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202410329249.0A Pending CN118319950A (zh) | 2020-03-20 | 2021-03-19 | 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途 |
| CN202180022924.XA Pending CN115335065A (zh) | 2020-03-20 | 2021-03-19 | 细胞培养组合物及其用途 |
| CN202180014788.XA Active CN115315265B (zh) | 2020-03-20 | 2021-03-19 | 线粒体用于促进伤口修复及/或伤口愈合的用途 |
| CN202180014777.1A Active CN115103683B (zh) | 2020-03-20 | 2021-03-19 | 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途 |
| CN202180014670.7A Active CN115135328B (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202311621466.9A Pending CN117379458A (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202180022422.7A Active CN115297872B (zh) | 2020-03-20 | 2021-03-22 | 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 |
| CN202410414731.4A Pending CN118252850A (zh) | 2020-03-20 | 2021-03-22 | 含有线粒体的组合物 |
| CN202180022370.3A Pending CN115315248A (zh) | 2020-03-20 | 2021-03-22 | 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途 |
| CN202410414725.9A Pending CN118236473A (zh) | 2020-03-20 | 2021-03-22 | 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物 |
Family Applications Before (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410329264.5A Pending CN118319951A (zh) | 2020-03-20 | 2021-03-19 | 修复肌腱损伤的组合物 |
| CN202311570784.7A Pending CN117357559A (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202410329249.0A Pending CN118319950A (zh) | 2020-03-20 | 2021-03-19 | 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途 |
| CN202180022924.XA Pending CN115335065A (zh) | 2020-03-20 | 2021-03-19 | 细胞培养组合物及其用途 |
| CN202180014788.XA Active CN115315265B (zh) | 2020-03-20 | 2021-03-19 | 线粒体用于促进伤口修复及/或伤口愈合的用途 |
| CN202180014777.1A Active CN115103683B (zh) | 2020-03-20 | 2021-03-19 | 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途 |
| CN202180014670.7A Active CN115135328B (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202311621466.9A Pending CN117379458A (zh) | 2020-03-20 | 2021-03-19 | 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途 |
| CN202180022422.7A Active CN115297872B (zh) | 2020-03-20 | 2021-03-22 | 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 |
| CN202410414731.4A Pending CN118252850A (zh) | 2020-03-20 | 2021-03-22 | 含有线粒体的组合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410414725.9A Pending CN118236473A (zh) | 2020-03-20 | 2021-03-22 | 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (6) | US20230137870A1 (zh) |
| EP (2) | EP4122474A4 (zh) |
| JP (1) | JP2023518083A (zh) |
| CN (12) | CN118319951A (zh) |
| TW (8) | TW202404618A (zh) |
| WO (6) | WO2021185341A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116478920A (zh) * | 2023-05-05 | 2023-07-25 | 重庆理工大学 | 一种离体线粒体的体外储存方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105520891A (zh) * | 2014-09-30 | 2016-04-27 | 李德财 | 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法 |
| WO2018178970A1 (en) * | 2017-03-26 | 2018-10-04 | Minovia Therapeutics Ltd. | Mitochondrial compositions and methods for treatment of skin and hair |
| CN110638833A (zh) * | 2019-11-15 | 2020-01-03 | 西安圣德生物科技有限公司 | 促进毛发生长的组合物及其使用方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7005274B1 (en) * | 1999-09-15 | 2006-02-28 | Migenix Corp. | Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass |
| BRPI0507349A (pt) * | 2004-02-02 | 2007-04-17 | Nestec Sa | genes associados á osteoartrite canina e processos e composições relacionados |
| WO2009002811A2 (en) * | 2007-06-22 | 2008-12-31 | Children's Medical Center Corporation | Therapeutic platelet compositions and methods |
| US8734854B2 (en) * | 2009-07-09 | 2014-05-27 | Orogen Biosciences Inc. | Process for removing growth factors from platelets |
| US20130022666A1 (en) * | 2011-07-20 | 2013-01-24 | Anna Brzezinska | Methods and compositions for transfer of mitochondria into mammalian cells |
| WO2013035101A1 (en) * | 2011-09-11 | 2013-03-14 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
| EP2591812A1 (en) * | 2011-11-14 | 2013-05-15 | University of Twente, Institute for Biomedical Technology and Technical Medicine (MIRA) | A dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair |
| US20140024677A1 (en) * | 2012-04-09 | 2014-01-23 | Musc Foundation For Research Development | Methods for inducing mitochondrial biogenesis |
| US10702556B2 (en) * | 2012-05-16 | 2020-07-07 | Minovia Therpautices Ltd. | Compositions and methods for inducing angiogenesis |
| WO2014121481A1 (zh) * | 2013-02-07 | 2014-08-14 | 李震义 | 长效人重组可溶性肿瘤坏死因子α受体在制备预防和治疗慢性肝病重症肝损伤药物中的用途 |
| US20150064715A1 (en) * | 2013-08-28 | 2015-03-05 | Musc Foundation For Research Development | Urinary biomarkers of renal and mitochondrial dysfunction |
| TW201509425A (zh) * | 2013-09-13 | 2015-03-16 | Taichung Hospital Ministry Of Health And Welfare | 以血液製備修復傷口用醫藥組合物之方法 |
| TWI672147B (zh) * | 2014-09-10 | 2019-09-21 | 台灣粒線體應用技術股份有限公司 | 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法 |
| WO2016106660A1 (zh) * | 2014-12-31 | 2016-07-07 | 国立中兴大学 | 新颖医药组合物及其用于治疗肺损伤的用途 |
| BR112017015004A2 (pt) * | 2015-01-15 | 2018-01-23 | K Boss William Jr | reparação e rejuvenescimento de tecidos usando plasma rico em plaquetas. |
| CN104546915B (zh) * | 2015-02-16 | 2018-12-11 | 天晴干细胞股份有限公司 | 一种治疗骨性关节炎的组合物的制备方法 |
| JP7015169B2 (ja) * | 2015-02-26 | 2022-02-02 | ミノヴィア セラピューティクス リミテッド | 機能性ミトコンドリアで富化された哺乳動物細胞 |
| CN105030647B (zh) * | 2015-09-14 | 2018-04-24 | 广州赛莱拉干细胞科技股份有限公司 | 一种减少皱纹的制剂及其制备方法 |
| JP2018535749A (ja) * | 2015-11-02 | 2018-12-06 | ベリグラフト アーベー | 創傷を治癒するための組成物および方法 |
| CN105477018A (zh) * | 2015-12-07 | 2016-04-13 | 深圳爱生再生医学科技有限公司 | 修复皮肤溃疡的干细胞制剂及其制备方法 |
| CN109152795A (zh) * | 2016-01-15 | 2019-01-04 | 儿童医学中心公司 | 线粒体和组合的线粒体试剂的治疗用途 |
| US20170224764A1 (en) * | 2016-02-10 | 2017-08-10 | Cornell University | Therapeutic targeting of mitochondria to prevent osteoarthritis |
| TWI637748B (zh) * | 2016-07-12 | 2018-10-11 | 中山醫學大學 | 蓮蓬萃取物用於治療及／或預防腎臟病變之用途 |
| CN106190963A (zh) * | 2016-07-13 | 2016-12-07 | 浙江大学 | 一种采用线粒体移植促进损伤神经元存活的方法 |
| JP2020502078A (ja) * | 2016-11-30 | 2020-01-23 | パイアン・バイオテクノロジー・インコーポレイテッドＰａｅａｎ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｉｎｃ． | ミトコンドリアを含む医薬組成物 |
| CN106822183B (zh) * | 2016-12-26 | 2020-04-14 | 中山光禾医疗科技有限公司 | 一种光敏富血小板血浆凝胶及其制备方法和用途 |
| EP3624830A4 (en) * | 2017-05-15 | 2020-12-30 | Miron, Richard J. | LIQUID LABEL-RICH FIBRIN AS A CARRIER SYSTEM FOR BIOMATERIALS AND BIOMOLECULES |
| US10940241B2 (en) * | 2017-06-01 | 2021-03-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Formation of stable cartilage |
| US20190008896A1 (en) * | 2017-07-07 | 2019-01-10 | Richard Postrel | Methods and Systems for the Prevention, Treatment and Management of Disease and Effects of Aging Via Cell-to-Cell Restoration Therapy Using Subcellular Transactions |
| CN107625969A (zh) * | 2017-10-18 | 2018-01-26 | 南京市儿童医院 | MiR‑214拮抗剂在制备用于减轻蛋白尿引起的肾小管损伤相关病症的药物中的用途 |
| WO2019083201A2 (ko) * | 2017-10-24 | 2019-05-02 | 주식회사 엑소코바이오 | 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도 |
| KR20190052266A (ko) * | 2017-11-08 | 2019-05-16 | 원광대학교산학협력단 | 우르솔산을 유효성분으로 포함하는 신장 기능의 개선 또는 치료용 조성물 |
| EP3747449A4 (en) * | 2018-02-02 | 2021-10-20 | Paean Biotechnology Inc. | PHARMACEUTICAL COMPOSITION CONSISTING OF ISOLATED MITOCHONDRIA FOR THE PREVENTION OR TREATMENT OF RHEUMATOID ARTHRITIS |
| CA3093823A1 (en) * | 2018-03-13 | 2019-09-19 | The Board Of Trustees Of The Leland Stanford Junior University | Transient cellular reprogramming for reversal of cell aging |
| WO2019183042A1 (en) * | 2018-03-20 | 2019-09-26 | Unity Biotechnology, Inc. | Autologous mitochondrial extraction and expansion |
| US20210275587A1 (en) * | 2018-07-22 | 2021-09-09 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of renal diseases |
| AU2019311862A1 (en) * | 2018-07-22 | 2021-02-04 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria |
| WO2020054829A1 (ja) * | 2018-09-14 | 2020-03-19 | ルカ・サイエンス株式会社 | ミトコンドリアのリンパ器官への移植およびそのための組成物 |
| WO2020091463A1 (ko) * | 2018-10-31 | 2020-05-07 | 차의과학대학교 산학협력단 | 분리된 미토콘드리아를 포함하는 건병증 예방 또는 치료용 약학 조성물 |
| CN110055216A (zh) * | 2019-05-09 | 2019-07-26 | 张秀明 | 一种改善间质干细胞生物学功能的方法 |
| CN110812480B (zh) * | 2019-11-28 | 2021-04-02 | 中国科学院昆明动物研究所 | 一种抗菌肽和线粒体dna复合物及其多克隆抗体和应用 |
-
2021
- 2021-03-18 TW TW112139490A patent/TW202404618A/zh unknown
- 2021-03-18 TW TW111140519A patent/TWI827321B/zh active
- 2021-03-18 TW TW110109766A patent/TWI789723B/zh active
- 2021-03-18 TW TW110109767A patent/TWI789724B/zh active
- 2021-03-18 TW TW110109765A patent/TWI787761B/zh active
- 2021-03-19 CN CN202410329264.5A patent/CN118319951A/zh active Pending
- 2021-03-19 EP EP21770630.8A patent/EP4122474A4/en active Pending
- 2021-03-19 JP JP2022556517A patent/JP2023518083A/ja active Pending
- 2021-03-19 CN CN202311570784.7A patent/CN117357559A/zh active Pending
- 2021-03-19 WO PCT/CN2021/081686 patent/WO2021185341A1/zh active Application Filing
- 2021-03-19 US US17/912,394 patent/US20230137870A1/en active Pending
- 2021-03-19 WO PCT/CN2021/081854 patent/WO2021185364A1/zh active Application Filing
- 2021-03-19 CN CN202410329249.0A patent/CN118319950A/zh active Pending
- 2021-03-19 TW TW110109874A patent/TWI796653B/zh active
- 2021-03-19 CN CN202180022924.XA patent/CN115335065A/zh active Pending
- 2021-03-19 CN CN202180014788.XA patent/CN115315265B/zh active Active
- 2021-03-19 WO PCT/CN2021/081685 patent/WO2021185340A1/zh active Application Filing
- 2021-03-19 TW TW111141019A patent/TW202308668A/zh unknown
- 2021-03-19 CN CN202180014777.1A patent/CN115103683B/zh active Active
- 2021-03-19 WO PCT/CN2021/081687 patent/WO2021185342A1/zh active Application Filing
- 2021-03-19 US US17/912,336 patent/US20230042445A1/en active Pending
- 2021-03-19 US US17/912,458 patent/US20230165899A1/en active Pending
- 2021-03-19 CN CN202180014670.7A patent/CN115135328B/zh active Active
- 2021-03-19 TW TW110109873A patent/TWI787763B/zh active
- 2021-03-19 CN CN202311621466.9A patent/CN117379458A/zh active Pending
- 2021-03-22 EP EP21770632.4A patent/EP4122444A4/en active Pending
- 2021-03-22 CN CN202180022422.7A patent/CN115297872B/zh active Active
- 2021-03-22 CN CN202410414731.4A patent/CN118252850A/zh active Pending
- 2021-03-22 CN CN202180022370.3A patent/CN115315248A/zh active Pending
- 2021-03-22 WO PCT/CN2021/082094 patent/WO2021185376A1/zh active Application Filing
- 2021-03-22 CN CN202410414725.9A patent/CN118236473A/zh active Pending
- 2021-03-22 WO PCT/CN2021/082117 patent/WO2021185377A1/zh active Application Filing
-
2022
- 2022-09-19 US US17/948,007 patent/US20230023438A1/en active Pending
- 2022-09-19 US US17/947,994 patent/US20230023218A1/en active Pending
- 2022-09-20 US US17/948,764 patent/US20230016499A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105520891A (zh) * | 2014-09-30 | 2016-04-27 | 李德财 | 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法 |
| WO2018178970A1 (en) * | 2017-03-26 | 2018-10-04 | Minovia Therapeutics Ltd. | Mitochondrial compositions and methods for treatment of skin and hair |
| CN110638833A (zh) * | 2019-11-15 | 2020-01-03 | 西安圣德生物科技有限公司 | 促进毛发生长的组合物及其使用方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bollini et al. | In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells | |
| Roy et al. | Platelet‐rich fibrin matrix improves wound angiogenesis via inducing endothelial cell proliferation | |
| Badillo et al. | Treatment of diabetic wounds with fetal murine mesenchymal stromal cells enhances wound closure | |
| Lv et al. | Adipose‐derived stem cells regulate metabolic homeostasis and delay aging by promoting mitophagy | |
| Trivisonno et al. | Harvest of superficial layers of fat with a microcannula and isolation of adipose tissue–derived stromal and vascular cells | |
| KR101655780B1 (ko) | 클로날 중간엽 줄기세포를 포함하는, 아토피성 피부염 예방 또는 치료용 약학적 조성물 | |
| CN108430480A (zh) | 一种包含过表达sod3的干细胞作为活性成分的炎症性疾病的预防或治疗用组合物 | |
| US20210322485A1 (en) | Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria | |
| Gaur et al. | Methods and strategies for procurement, isolation, characterization, and assessment of senescence of human mesenchymal stem cells from adipose tissue | |
| Jung et al. | Hyaluronic acid decreases lipid synthesis in sebaceous glands | |
| He et al. | Participation of CD34-enriched mouse adipose cells in hair morphogenesis | |
| CN115315248A (zh) | 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途 | |
| US10017817B2 (en) | Skin activation by acceleration of PDGF-BB activity | |
| Wang et al. | Patterns of nestin expression in human skin | |
| US20200255799A1 (en) | Method for the production of hair follicles and de novo papillae, and use thereof for in vitro tests and in vivo implants | |
| TWI849298B (zh) | 促進毛髮再生的富粒線體血漿、其製造方法及其用途 | |
| KR20200103718A (ko) | 인간 피부 섬유아세포의 분리 방법 | |
| TW201504435A (zh) | 毛囊形成用組合物之品質管理方法 | |
| Kitamura | Flow of CD11b+ cytometric Gr-1+ detection cells in nontumor-bearing mice: A propolis-elicited model | |
| Balaji et al. | Pluripotent lineage of CD133 stem cells isolated from human skin samples | |
| Putman et al. | Isolation of Human Umbilical Cord Blood Aldehyde Dehydrogenase–Expressing Progenitor Cells that Modulate Vascular Regenerative Functions In Vitro and In Vivo | |
| Fujiwara et al. | Effect of platelet lysate on Schwann-like cell differentiation of equine bone marrow-derived mesenchymal stem cells | |
| WO2013044607A1 (zh) | 一种自体脂肪干细胞抗衰老效果的评价体系 | |
| Griffoni | Towards advanced immunocompetent skin wound models for in vitro drug evaluation | |
| CN115232786B (zh) | 一种脂肪干细胞外泌体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |